Background: NEJ005/TCOG0902 study has demonstrated that first-line concurrent (C) and sequential alternating (S) combination therapies of EGFR tyrosine kinase inhibitor (gefitinib) plus platinum-based doublet chemotherapy (carboplatin/pemetrexed) offer promising efficacy with predictable toxicities for patients with EGFRmutant non-small cell lung cancer (ASCO2014, Ann Oncol 2015). However, overall survival (OS) data were insufficient because of the lack of death events in the primary report. Methods: Progression-free survival (PFS) and OS were re-evaluated at the final data cutoff point (November 2016) for the entire population (N ¼ 80). Results: At the median follow-up time of 35.6 months, 88.8% of patients had progressive disease and 72.5% of patients had died. Median PFS was 17.5 months for the C regimen and 15.3 months for the S regimen (p ¼ 0.13). Median OS time was 43.3 with the C regimen and 30.7 months with the S regimen (p ¼ 0.018). Updated response rates were similar in both groups (90.2% and 82.1%, respectively; p ¼ 0.34). Patients who had common mutations showed no significant differences in PFS according to type of mutation. Patients with Del19 displayed relatively better OS (median: 45.3 and 33.3 months for C and S regimens) than those with L858R (31.4 and 28.9 months). No severe adverse events including interstitial lung disease have occurred during the follow-up period since the primary report.
Background: Crizotinib has shown marked antitumor activity in ROS1þ advanced NSCLC. We present the updated results from a ph II study of crizotinib in East Asian pts with ALK-advanced NSCLC who harbor a ROS1-rearrangement.
Methods:
In this ongoing open-label, single-arm ph II study (NCT01945021), pts with ROS1þ, ALK-NSCLC who had received 3 lines of prior systemic treatment (tx) received crizotinib, 250 mg BID. Tx was continued until RECIST-defined progression (determined by independent radiology review, IRR), unacceptable toxicity or withdrawal of consent. Pts could continue on tx for ongoing clinical benefit at the investigator's discretion. Primary endpoint was ORR by IRR. Secondary efficacy measures and safety were also assessed. Results: From Sept 2013 to Jan 2015, 129 pts enrolled at 37 sites in China, Japan, Korea and Taiwan. 127 pts were included in the antitumor and safety analyses. ORR by IRR was 72% (95% CI 63, 79) in the overall population and 65% (95%CI 44, 83) in Japan. ORRs were similar irrespective of enrolment country (65-78%) or number of prior lines of therapy (65-79%). Reponses were mostly observed within the first 2 months and were durable (median duration of response 20 months (95% CI 14, not reached, NR). Median PFS was 16 months (95% CI 13, 24); 45 pts (35%) were in follow-up for PFS at data cut off (30 Jul 2016). Disease control rates were 88% and 80% at weeks 8 and 16, respectively. Overall survival data was not mature (median OS 33 months, 95% CI: 33, NR) as 60% of pts were alive at last follow-up. Most frequently reported all causality AEs were elevated transaminases (60%), vision disorder (50%), diarrhea (47%) and nausea (44%). None of the grade 5 events reported were tx-related. Conclusion: These data show that crizotinib provides a meaningful clinical benefit in East Asian pts with ROS1þ advanced NSCLC. Crizotinib was generally well tolerated, with a safety profile consistent with previous reports.
O3 À 6 À 1 Interim safety analysis of a phase II trial of modified-FOXFOXIRI plus bevacizumab for RAS mutant mCRC (JACCRO CC-11) Background: The TRIBE study confirmed FOLFOXIRI plus bevacizumab (bev) as a standard initial therapy for mCRC; the triplet should be one of preferred regimens in RAS mutant (mt) tumors. However, frequent severe adverse events (AEs) such as febrile neutropenia (FN) were reported in Japanese patients (pts) (Oki, et al. JSMO 2016) . We performed a phase II trial to assess the safety and activity of modified-FOLFOXIRI plus bev in RAS mt mCRC pts (UMIN000015152). 2 on day 1, and fluorouracil 2400 mg/m 2 for 46-h continuous infusion starting on day 1 and repeated every 2 weeks) as 1st-line treatment in multi-institutes. After induction therapy of a maximum of 12 cycles, maintenance therapy with fluorouracil/LV plus bev was administered. The primary endpoint was response rate. The interim safety analysis was performed in 1st-cycle of 6 pts as previously planned. Results: The interim analysis showed that common any AEs were neutropenia (33%), appetite loss (67%), diarrhea (67%), and fatigue (50%). No unexpected AEs were observed; 2 pts for Gr 3/4 neutropenia with no FN and 1 pt for Gr 3 nausea. This study was proceeded according to recommendation of IDMC, a total of 64 pts were enrolled. At January 2017, 63 pts were evaluable for safety analysis; median 63-y old (36-75), 56% male, 91% PS0, 29% right-sided tumor pts, and median cycle of 9. AEs of Gr 3/4 were neutropenia (48%), hypertension (19%), diarrhea (11%), FN (4.8% for all, 0% for pts <70-y), appetite loss (9.5%), and nausea (7.9%) during the cycles (range 1-33). 60% pts still continued the treatment and just one (1/24) discontinued due to toxicity. Conclusions: This safety analysis demonstrates that modified-FOLFOXIRI plus bev is less toxic and may be more manageable for Japanese mCRC pts. Background: Each CEA decrease and good depth of response (DpR) correlated with prolonged survival in metastatic colorectal cancer (mCRC) patients (pts) receiving cetuximab (cet) therapy. Most right-sided tumors receive no benefit from cet in survival time; however, it is controversial in objective response. Methods: This study evaluated the associations between the percentage of CEA decrease, DpR, and clinical outcomes in KRAS exon 2 wild-type mCRC pts enrolled in phase II trials (JACCRO CC-05 of cet plus FOLFOX; UMIN000004197, CC-06 of cet plus SOX; UMIN000007022). The association was analyzed using Spearman's rank correlation coefficient. The cut-off value of 75% CEA decrease was used for discriminating CEA responders. In addition, exploratory analyses were performed by primary tumor sidedness. Results: 92 pts were eligible for analyses; 17 right-sided tumor pts, median PFS of 9.1 m, and median OS of 36.2 m. Median CEA decrease was 67.4% and median time to CEA nadir was 2.8 m similar to median time to DpR of 3.0 m. The DpR was associated with PFS and OS (r s ¼0.56; P<0.0001, r s ¼0.39; P¼0.0090, respectively). The CEA decrease also correlated with PFS (r s ¼0.56, P<0.0001) as well as OS (r s ¼0.35, P¼0.019). In addition, the DpR and CEA decrease had significant associations with PFS in each side. CEA responders showed significantly longer PFS (11.8 vs. 5.5 m; HR 0.46; P¼0.0009) and numerically longer OS (36.2 vs. 23.5 m; HR 0.57; P¼0.072) than CEA non-responders; PFS of the responders was longer in each side (left; 11.7 vs. 5.6 m, P¼0.04, right; 15.9 vs. 3.2 m, P¼0.07). The CEA decrease was statistically significantly associated with DpR regardless of tumor sidedness (r s ¼0.44, P<0.0001, left; r s ¼0.39, P¼0.0006, right; r s ¼0.53, P¼0.031).
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